{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001387","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.783161+00:00","generated_at":"2026-05-28T11:38:14.372463+00:00","sec_items":["1.01","3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adagio Medical enters waiver for defaults, receives Nasdaq non-compliance letter","bullets":["Issued 183,333 restricted shares at $2.00 per share to settle registration delay payments with buyers.","Buyers waived defaults including misstated financials that caused delayed payments and lapsed registration.","Received Nasdaq notice for audit committee vacancy after Shahram Moaddeb's resignation; cure period until Jan 2, 2026.","Company must file a new registration statement by February 28, 2025 per waiver terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001387","json":"https://secwatch.observer/filing/0001104659-25-001387.json","markdown":"https://secwatch.observer/filing/0001104659-25-001387.md","text":"https://secwatch.observer/filing/0001104659-25-001387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925001387/0001104659-25-001387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925001387/tm2432281d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T11:38:14.372463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"642808584ee50f9b9751c5ec0812f878ba404b9a","claim":"Adagio Medical Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(4)).","evidence_excerpt":"January 2, 2025, the Company r eceived a letter from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, due to the vacancy on the audit committee of the Company’","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925001387/0001104659-25-001387-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605(c)(4)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"befa228c1ae988a651cb4a02d5225ea6fb72319a","claim":"Adagio Medical Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).","evidence_excerpt":"January 2, 2025, the Company r eceived a letter from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, due to the vacancy on the audit committee of the Company’s Board of Directors (the “ Board ”) following Shahram Moaddeb’s resignation from the Board as disclosed in the Company's Current Report on Form 8-K filed with the SEC on December 23, 2024, the Company is not in compliance with Nasdaq’s audit committee requirements as set forth in Listing Rule 5605. Under Nasdaq Listing Rule 5605(c)(4), Nasdaq provided the Company a cure period","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925001387/0001104659-25-001387-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605, 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}